VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
01 sept. 2022 16h30 HE
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases,...
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
15 août 2022 16h05 HE
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today...
VBL Therapeutics Announces Workforce Reduction
02 août 2022 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases,...
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
19 juil. 2022 16h01 HE
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases,...
VBL Therapeutics to Participate in the Jefferies Healthcare Conference
31 mai 2022 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
17 mai 2022 07h00 HE
|
VBL Therapeutics
OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV,...
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
10 mai 2022 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for...
VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May
03 mai 2022 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for...
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
28 avr. 2022 16h05 HE
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
26 avr. 2022 08h00 HE
|
VBL Therapeutics
FDA grants Fast Track designation to facilitate development and expedite the review of therapies with potential to treat serious unmet medical needs. The purpose of this designation is to bring...